סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma (malta) limited - omeprazol - gastrorezistentna kapsula, trda - omeprazol 40 mg / 1 kapsula - omeprazol

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma (malta) limited - piperacilin; tazobaktam - prašek za raztopino za injiciranje/infundiranje - piperacilin 2 g / 1 viala  tazobaktam0,25 g / 1 viala; tazobaktam 0,25 g / 1 viala - piperacilin in zaviralec laktamaz beta

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma (malta) limited - piperacilin; tazobaktam - prašek za raztopino za injiciranje/infundiranje - piperacilin 2 g / 1 viala  tazobaktam0,25 g / 1 viala; tazobaktam 0,25 g / 1 viala - piperacilin in zaviralec laktamaz beta

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma (malta) limited - piperacilin; tazobaktam - prašek za raztopino za injiciranje/infundiranje - piperacilin 4 g / 1 viala  tazobaktam0,5 g / 1 viala; tazobaktam 0,5 g / 1 viala - piperacilin in zaviralec laktamaz beta

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma (malta) limited - piperacilin; tazobaktam - prašek za raztopino za injiciranje/infundiranje - piperacilin 4 g / 1 viala  tazobaktam0,5 g / 1 viala; tazobaktam 0,5 g / 1 viala - piperacilin in zaviralec laktamaz beta

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi dihal - orkambi tablete so primerna za zdravljenje cistična fibroza (cf) pri bolnikih, starih 6 let in več, ki so homozygous za f508del mutacije v cftr gena. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi dihal - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aspen pharma trading limited - azatioprin - filmsko obložena tableta - azatioprin 50 mg / 1 tableta - azatioprin

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena.